Supernus Pharmaceuticals SUPN Available-for-Sale Debt Securities
Available-for-Sale Debt Securities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's available-for-sale debt securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's available-for-sale debt securities?
- Supernus Pharmaceuticals (SUPN) reported available-for-sale debt securities of $199.37M in Q1 2026.
- How has Supernus Pharmaceuticals's available-for-sale debt securities changed year-over-year?
- Supernus Pharmaceuticals's available-for-sale debt securities decreased by 42.7% year-over-year, from $347.74M to $199.37M.
- What is the long-term trend for Supernus Pharmaceuticals's available-for-sale debt securities?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's available-for-sale debt securities has grown at a -21.2% compound annual growth rate (CAGR), from $368.21M to $180.22M.
- What does available-for-sale debt securities mean?
- This represents the fair value of debt securities held by the company that are not classified as trading or held-to-maturity. These assets reflect the company's liquidity strategy for excess cash and are subject to market price fluctuations, with unrealized gains or losses recorded in other comprehensive income. Monitoring this balance helps investors assess the company's exposure to interest rate risk and its ability to deploy capital for future strategic needs.